Skip to content

Investigating Biological Targets, Markers, and Intervention for Chronic Pain

Investigating Biological Targets, Markers, and Intervention for Chronic Pain

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04625504
Enrollment
69
Registered
2020-11-12
Start date
2020-11-25
Completion date
2022-07-28
Last updated
2023-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain, Pain, Chronic, Pain, Intractable, Pain, Neuropathic, Pain Syndrome

Keywords

Neurophysiology, Endocrine, EEG/ERP, Cognitive, Mindfulness, Mechanistic Clinical Trial

Brief summary

This multi-modal methods study will investigate neurophysiological, endocrinological, cognitive, psycho-social-emotional markers of chronic pain, and therapeutic targets using integrative health treatments.

Detailed description

It is estimated that 50 million adults in the USA suffer from chronic pain. Chronic pain is one of the most common reasons adults seek medical care, causing undue burden on primary care channels and treatment costs. Chronic pain is associated with (1) restrictions in mobility and daily activity, (2) dependence on opioids, (3) anxiety and depression, and (4) poor perceived health and reduced quality of life. Developing robust and specific non-pharmacologic intervention programs, on par with pharmacological clinical outcomes without harmful side-effects, addictive risk, and toxicity, is a crucial unmet clinical need and a research priority for the NCCIH. Understanding the mechanistic pathways of these interventions is key to their clinical development and implementation for treating chronic pain in primary care. Mindfulness-Based Interventions (MBIs) show similar clinical efficacy for mood disorders as pharmacology, and co-morbid symptoms of depression and anxiety. Meta-analysis including 183 patients with Multiple Sclerosis showed efficacy in psychosocial outcomes, quality of life, anxiety, depression, and select physical symptoms including fatigue, pain, and vestibular symptoms. The clinical efficacy of MBIs appears to extend mood disorders, as a systematic review including 13 studies in fibromyalgia, chronic fatigue, and irritable bowel syndrome showed significant effect sizes, reported as standardized mean difference (SMD), compared to control conditions in reducing symptom severity (SMD= -.40), and pain (SMD= -.21). Cognitively, MBIs appear to enhance executive control and self-regulatory processing, that has a beneficial effect upon emotion regulation, pain perception, and has shown to reduce ruminative ideation. Previous research has also suggested that mindfulness meditation training improves chronic pain symptomology through certain mechanisms such as disengagement from pain-related threats. While previous research has shown MBIs to be effective in treating certain health conditions, the mechanisms by which MBIs lead to clinical changes remain unclear. No study has adequately investigated biological or neurophysiological markers in chronic pain that may correlate with reduction in clinical symptoms. This overarching study aims to identify key phenotypic markers and treatment targets of chronic pain, and further understand MBI mechanism in its treatment.

Interventions

Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed

Sponsors

Vanderbilt University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

for Chronic Pain Patients: * Age range: 18-60 years * Must indicate pain intensity of 3/10 and must have experienced pain for at least 3 months * Must possess English language skills sufficient for providing informed consent, completing questionnaires, and understanding instructions * Must have a stable medication regimen or no medication or dosage changes within the past month Blood Collection Inclusion: * At least 110 pounds * Generally healthy by self-report on day of collection (i.e., free of cold and flu symptoms on the day of collection, no infections within two weeks prior to collection, no known sickle cell disease) * Including the study draw, blood donation for clinical or research purposes within the preceding eight weeks will not exceed 550 mL * No more than one blood draw will have occurred during the preceding week

Exclusion criteria

for Chronic Pain Patients: * Prior diagnosis of bipolar I, bipolar II, psychotic personality disorder, borderline personality disorder, and/or narcissistic personality disorder * Current history (equal/less than 6 months) of substance abuse/dependence * Current history (equal/less than 6 months) of regular meditation practice (\>1 session/week; \>10 min/session) * Diagnosis of bipolar I, bipolar II, psychotic personality disorder, borderline personality disorder, and/or narcissistic personality disorder * History of medical illness associated with possible changes in cerebral tissue or cerebrovasculature (e.g., stroke) or with neurologic abnormality (e.g., seizure disorder, cerebrovascular or neoplastic lesion, neurodegenerative disorder, or significant head trauma, defined by loss of consciousness of ≥ 5 minutes) * Current suicidal ideation

Design outcomes

Primary

MeasureTime frameDescription
Electroencephalography (EEG)36 monthsOscillatory Activity

Secondary

MeasureTime frameDescription
Endocrine Measures36 monthsCortisol, Oxytocin
Cognitive-Behavioral Measure36 monthsExecutive Inhibitory Control

Other

MeasureTime frameDescription
Clinical: Pain Measure36 monthsMcGill Pain Questionnaire; Score range: 0 -- 45, with higher scores indicating worse outcomes.
Clinical: Interoception36 monthsMultidimensional Assessment of Interoceptive Awareness; 8 subdomains, Score range: 0 -- 5, with higher scores indicating more interoceptiveness
Clinical: General Symptoms36 monthsPatient Reported Outcomes Measurement Information System; Score range: 4 -- 20, with higher scores indicating worse outcomes
Clinical: Mindfulness Skills36 monthsFive Facet Mindfulness Questionnaire; 5 domains, Score range: 0 -- 8, with higher scores indicating more mindfulness skills.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026